Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection

NCT05242159 | Recruiting

• 1 other identifier: PI2021_843_0120
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

In January 2020, researchers isolated and sequenced in China from patients with severe atypical pneumonia a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread throughout the world. SARS-CoV-2 may trigger hyperstimulation of immune system with an autoinflammatory response but also the development of an autoimmune process. These autoimmune responses may also develop through the molecular mimicry between virus and human-self components. Multiple autoantibodies have been described in COVID-19 patients. Annexin A2 (ANXA2), an endothelial cell receptor for plasminogen and tissue plasminogen activator has been identified as a new autoantigen in antiphospholipid syndrome. ANXA2 has been identified as candidate autoantigen recognized by SARS patient sera. ANXA2 contributes also to pulmonary microvascular integrity. These data lead to identify anti-ANXA2 antibodies in COVID-19 patient sera and to know if the presence of these antibodies is associated with pulmonary injury or thrombosis in COVID-19 and represents a marker of severity.

Conditions

COVID-19

Keywords

COVID-19; annexin A2

Outcome Measures

Primary Outcomes (1)

• Prevalence of anti-ANXA2 antibodies in patients with COVID-19 infection

  6 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients hospitalized in Amiens University Hospital with COVID-19 infection

You may qualify if:

• years and older
• All patients hospitalized in Amiens University Hospital with COVID-19 infection

You may not qualify if:

• Autoimmune diseases
• Chronic viral infection by hepatitis B virus, hepatitis C virus or human immunodeficiency virus (HIV)
• Immunosuppressive treatment
• Solid tumors
• Hematological malignancies

Sponsors & Collaborators

• Centre Hospitalier Universitaire, Amiens: lead

Study Sites (1)

CHU Amiens

Amiens, 80054, France

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

blood samples

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Valéry Salle, MD

CONTACT

03 22 66 82 30; salle.valery@chu-amiens.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 15, 2022
• First Posted: February 16, 2022
• Study Start: May 28, 2021
• Primary Completion: June 1, 2026
• Study Completion: June 1, 2026
• Last Updated: June 15, 2026

Record last verified: 2026-06

Locations

FR (1)